{"id":"NCT03536884","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","officialTitle":"A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-13","primaryCompletion":"2019-09-12","completion":"2023-08-09","firstPosted":"2018-05-25","resultsPosted":"2022-10-10","lastUpdate":"2025-01-14"},"enrollment":743,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Plaque Psoriasis","Moderate to Severe Chronic Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Bimekizumab","otherNames":["UCB4940"]},{"type":"DRUG","name":"Secukinumab","otherNames":["COSENTYX®"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"Bimekizumab dosage regimen 1","type":"EXPERIMENTAL"},{"label":"Bimekizumab dosage regimen 2","type":"EXPERIMENTAL"},{"label":"Secukinumab","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).","primaryOutcome":{"measure":"Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"ITP: Bimekizumab (BKZ) 320 mg Q4W","deltaMin":61.7,"sd":null},{"arm":"ITP: Secukinumab 300 mg Q4W","deltaMin":48.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":16,"exclusionCount":10},"locations":{"siteCount":77,"countries":["United States","Australia","Belgium","Canada","France","Germany","Netherlands","Poland","Spain","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["37182701","38588819","39578348","40886218","39862230","39285121","36751950","34471992","34001692","33891380"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm","https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":373},"commonTop":["Nasopharyngitis","Oral candidiasis","Upper respiratory tract infection","Urinary tract infection","Corona virus infection"]}}